Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s only substantive label-related claim—about the WARNING for spinal/epidural hematomas—is directly and fully supported by the provided FDA label text (Boxed Warning and related sections including Warnings and Precautions 5.1, Adverse Reactions, Postmarketing Experience, and Patient Counseling).
Category Scores
Accurate Statements
WARNING: SPINAL/EPIDURAL HEMATOMAS (risk described for anticoagulated patients receiving neuraxial anesthesia/spinal puncture; may result in long-term or permanent paralysis; boxed warning and related sections cross-reference Warnings and Precautions 5.1).
Supported by BOXED WARNING text and consistent with Warnings and Precautions 5.1 (e.g., reported epidural/spinal hemorrhage/hematomas resulting in long-term or permanent paralysis) and cross-references in Adverse Reactions (6) and Postmarketing Experience (6.2).
Patient counseling includes monitoring for signs/symptoms of spinal/epidural hematoma (e.g., tingling, numbness, weakness/neurological impairment) and seeking immediate medical attention if symptoms occur.
Supported by SECTION 17 Patient Counseling Information in the provided label text.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response aligns with the provided boxed warning and related label content for spinal/epidural hematoma risk and associated monitoring/counseling; no unsafe omissions or contradictions were identified in the evaluated warning-focused content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement